Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction

Journal of the American College of Cardiology

Volumn 63, Issue 6, 2014, Pages 513-517

  Perl, Leor ^a   Lerman Shivek, Hila ^a,b   Rechavia, Eldad ^a   Vaduganathan, Muthiah ^c   Leshem Lev, Dorit ^d   Zemer Wassercug, Noa ^a   Dadush, Oshrat ^d   Codner, Pablo ^a   Bental, Tamir ^a   Battler, Alexander ^a   Kornowski, Ran ^a   Lev, Eli I ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

antiplatelet therapy; pharmacology; ST segment elevation myocardial infarction

Indexed keywords

ANTIPLATELET THERAPY; PHARMACOLOGY; ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES;

PRASUGREL; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y12 RECEPTOR;

ADJUVANT THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ISRAEL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

EID: 84893852941     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.110     Document Type: Article

References (18)

1. J.A. Jakubowski, C.D. Payne, and J.T. Brandt et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects J Cardiovasc Pharmacol 47 2006 377 384 (Pubitemid 44309690)
2. T. Jernberg, C.D. Payne, and K.J. Winters et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
3. L. Bonello, M. Pansieri, and J. Mancini et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
4. A.D. Michelson, A.L. Frelinger 3rd, and E. Braunwald et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
5. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
6. G. Parodi, R. Valenti, and B. Bellandi et al. Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
7. J.L. Mega, S.L. Close, and S.D. Wiviott et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
8. C. Varenhorst, S. James, and D. Erlinge et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
9. T. Cuisset, M. Loosveld, and P.E. Morange et al. CYP2C19*2 and*17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome J Am Coll Cardiol Intv 5 2012 1280 1287
10. M.S. Robinson, I.J. Mackie, and K. Khair et al. Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes Br J Haematol 100 1998 351 357 (Pubitemid 28131070)
11. N. Lakkis, H. Dokainish, and M. Abuzahra et al. Reticulated platelets in acute coronary syndrome: a marker of platelet activity J Am Coll Cardiol 44 2004 2091 2093 (Pubitemid 39473299)
12. D.J. McCabe, P. Harrison, P.S. Sidhu, M.M. Brown, and S.J. Machin Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack Br J Haematol 126 2004 861 869 (Pubitemid 39273828)
13. S. Guthikonda, C.L. Alviar, and M. Vaduganathan et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease J Am Coll Cardiol 52 2008 743 749
14. L. Bonello, U.S. Tantry, and R. Marcucci et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
15. M.J. Price, D.J. Angiolillo, and P.S. Teirstein et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety Circulation 124 2011 1132 1137
16. S. Guthikonda, E.I. Lev, and R. Patel et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin J Thromb Haemost 5 2007 490 496 (Pubitemid 46680680)
17. S. Karpatkin Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets J Clin Invest 48 1969 1083 1087
18. K.A. Ault, H.M. Rinder, J. Mitchell, M.B. Carmody, C.P. Vary, and R.S. Hillman The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis Am J Clin Pathol 98 1992 637 646